Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 425

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma

Open access
Travis, Lois B., Hill, Deirdre, Dores, Graça M., Gospodarowicz, Mary, van Leeuwen, Flora E., Holowaty, Eric, Glimelius, Bengt, Andersson, Michael, Pukkala, Eero, Lynch, Charles F., Pee, David, Smith, Susan A., Van't Veer, Mars B., Joensuu, Timo, Storm, Hans, Stovall, Marilyn, Boice, John D., Gilbert, Ethel, Gail, Mitchell H.·2005·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. METHODS: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20- < 40 Gy, or > or = 40 Gy) and use of alkylating agents (yes or no) were estimated from a case-control study conducted within an international population-based cohort of 3817 female 1-year survivors of HL diagnosed at age 30 years or younger from January 1, 1965, through December 31, 1994. To compute cumulative absolute risks of breast cancer, we used modified standardized incidence ratios to relate cohort breast cancer risks to those in the general population, enabling application of population-based breast cancer rates, and we allowed for competing risks by using population-based mortality rates in female HL survivors. RESULTS: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. CONCLUSIONS: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/dji290

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 425

Metadata

Authors
Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C. F., Pee, D., Smith, S. A., Van't Veer, M. B., Joensuu, T., Storm, H., Stovall, M., Boice, J. D., Gilbert, E., & Gail, M. H.
Venue
JNCI: Journal of the National Cancer Institute
Published
2005-10-05
Volume
97
Issue
19
Pages
1428-1437
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2115362683
Cited by
425
References
33
FWCI
16.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. https://app.cochat.ai/papers/10.1093/jnci/dji290
The paper
Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C. F., Pee, D., Smith, S. A., Van't Veer, M. B., Joensuu, T., Storm, H., Stovall, M., Boice, J. D., Gilbert, E., & Gail, M. H. (2005). Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/dji290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.